KPV benefits and uses

How to read these findings

Every finding below comes from cells in a dish or from mice and rats. None comes from people: FDA's review dated May 12, 2026 found no clinical studies, no human pharmacokinetic data and no case reports for KPV.³ FDA's own reading of the lab and rodent work is that KPV may have anti-inflammatory and wound-healing properties in those models, while the molecules it acts on remain unknown.³ Each item below names its evidence level.

Gut inflammation in mice

Colitis is the most studied use. In a 2008 study, KPV in the drinking water reduced colitis caused by two different chemicals, DSS and TNBS, and lowered inflammatory cytokine expression; the paper reports groups of 5 to 10 mice.¹¹⁸ The same team showed in cells that KPV enters intestinal and immune cells through PepT1, a transporter for small peptides, and inhibits NF-kappa B and MAP kinase signaling at nanomolar concentrations.¹

A second 2008 group reported earlier recovery, stronger weight regain and fewer inflammatory cells in the colon in DSS colitis, plus recovery from colitis caused by transferred T cells.² All treated mice lacking working MC1 receptors survived DSS colitis, and the authors judged the effects at least partly independent of that receptor.²

How KPV was delivered changed the result. Packed into colon-targeted nanoparticles in an alginate and chitosan gel, it matched free KPV at a concentration 12,000 times lower (2010).¹⁰ Nanoparticles coated with hyaluronic acid protected the colon lining and lowered TNF-alpha better than uncoated ones (2017).¹¹ In a model of colitis-linked colon cancer, KPV prevented tumors in normal mice but had no effect in mice lacking PepT1 (2016).¹²

Mouth sores and wounds

In rats with mouth sores caused by chemotherapy (oral mucositis), a gel carrying KPV, applied to the gums, improved food intake, weight recovery and tissue repair, and lowered IL-1 beta and TNF-alpha.⁵ The gel also held EGCG, a plant compound with antibacterial activity of its own, and it had an antibacterial effect on MRSA-infected gum ulcers.⁵ FDA notes positive wound-healing studies in rodents but found no human data on wounds.³ A 2019 dermatology review named KPV and related peptides as promising candidates for the future treatment of skin wounds and ulcers.¹⁹

Skin cells

In human skin cells (HaCaT keratinocytes) exposed to fine dust (PM10), KPV at 50 micrograms per mL restored cell survival and lowered IL-1 beta, and it reduced inflammatory cell death in a 3D skin model (2025).¹⁵ Getting KPV into skin is a separate problem: in a lab test on human skin, it did not cross intact skin in detectable amounts by simple diffusion.²⁰ The one human-use form proposed to FDA, a 0.1% cream or gel for wounds and inflammatory skin conditions such as psoriasis and eczema, had no human data behind it.³

Brain injury

In a 2013 mouse study, one injection of KPV given shortly after a controlled brain injury led to smaller injuries and less nerve-cell death.¹³ Levels of the inflammatory markers TNF-alpha and IL-1 beta did not fall.¹³ The abstract reports no test of memory or focus, and FDA notes that websites claim KPV protects against nerve damage and stroke without human data to show it.³

Other inflammation and lab findings

• Peritonitis (2003, mice): KPV given systemically cut the build-up of neutrophils, a type of white blood cell, in the abdominal cavity.⁷ It also worked when IL-1 beta set off the inflammation and in mice without working MC1 receptors.⁷
• Ear swelling (1989, mice): graded doses reduced chemically induced swelling in step with the dose, compared with saline and a large dose of corticosteroid.¹⁴ FDA classes this study as testing N-acetylated KPV, a modified form.³
• Airway cells (2012, human cell line): KPV lowered NF-kappa B activity, MMP-9 activity and release of the chemokines IL-8 and eotaxin, more at higher concentrations.⁶
• Macrophages (2001, mouse cell line): KPV curbed nitric oxide production almost as strongly as full alpha-MSH.²¹
• Bacteria and yeast (2000 and 2011, lab dishes): KPV slowed colony formation of Staphylococcus aureus and reduced survival of the yeast Candida albicans.¹⁶ At micromolar concentrations it killed more than 90% of both methicillin-sensitive and methicillin-resistant S. aureus, damaging their membranes.¹⁷

Fat cells and body weight

One 2026 study reported less fat formation in fat precursor cells.⁸ In mice on a high-fat diet, oral KPV also reduced weight gain, fat tissue growth, liver enlargement and blood lipid problems.⁸ No other study in the sources reviewed has repeated this, and FDA found no human study of KPV.³ The wider evidence on peptides and weight is in Peptides and weight loss.

What the evidence does not show

• Tanning: no pigment effect has been reported for KPV.²² A 2010 review of lab and animal research reports that it keeps almost all of alpha-MSH's anti-inflammatory capacity but lacks any pigment action, and it did not compete for MC1 receptor binding in cell tests.²²²¹ See Peptides and tanning.
• Muscle: FDA notes KPV is promoted in compounded "regenerative combo" products with BPC-157, TB-500, AOD9604 and Follistatin-344 for muscle, joint and cartilage repair, and a 2026 review lists it among peptides promoted in sport for muscle growth and recovery.³⁹ None of the studies above measured muscle.
• Hair: no KPV study in the sources reviewed measured hair growth.
• People: no benefit of KPV has been measured in humans for any use.³

Related pages

The KPV profile covers what KPV is and its regulatory status. Safety is covered in KPV side effects, and the amounts these studies used are in KPV dosage. For KPV within a blend, see the KLOW Peptide Blend profile. Goal overviews: healing and recovery, skin and hair, focus and memory and muscle. Vial specifications and storage are on the KPV for sale page.